These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1364 related items for PubMed ID: 24169019

  • 21. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
    Stone GW, Clayton T, Deliargyris EN, Prats J, Mehran R, Pocock SJ.
    J Am Coll Cardiol; ; 63(1):15-20. PubMed ID: 24140664
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey TD, Fahy M, Parise H, Stone GW.
    JACC Cardiovasc Interv; 2011 Jul; 4(7):760-8. PubMed ID: 21777884
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
    Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O'Neill WW, Lansky AJ, Griffin JJ, CADILLAC Investigators.
    Am J Cardiol; 2006 Aug 01; 98(3):331-7. PubMed ID: 16860018
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparison of Outcomes and Prognosis of Patients With Versus Without Newly Diagnosed Diabetes Mellitus After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (the HORIZONS-AMI Study).
    Ertelt K, Brener SJ, Mehran R, Ben-Yehuda O, McAndrew T, Stone GW.
    Am J Cardiol; 2017 Jun 15; 119(12):1917-1923. PubMed ID: 28427734
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.
    Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, Mehran R, Stone GW.
    Am Heart J; 2011 Oct 15; 162(4):663-70. PubMed ID: 21982658
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials.
    Warren J, Mehran R, Baber U, Xu K, Giacoppo D, Gersh BJ, Guagliumi G, Witzenbichler B, Magnus Ohman E, Pocock SJ, Stone GW.
    Am Heart J; 2016 Jan 15; 171(1):40-7. PubMed ID: 26699599
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
    Bangalore S, Pencina MJ, Kleiman NS, Cohen DJ.
    Circ Cardiovasc Interv; 2014 Jun 15; 7(3):365-73. PubMed ID: 24736878
    [Abstract] [Full Text] [Related]

  • 37. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial.
    Kaltoft A, Kelbaek H, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, Engstrøm T, Bøtker HE, Saunamäki K, Krusell LR, Jørgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Køber L, Kofoed KF, Terkelsen CJ, Helqvist S.
    J Am Coll Cardiol; 2010 Aug 17; 56(8):641-5. PubMed ID: 20688033
    [Abstract] [Full Text] [Related]

  • 38. Determinants of bare-metal stent use in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Parikh PB, Jeremias A, Naidu SS, Brener SJ, Shlofmitz RA, Pappas T, Marzo KP, Gruberg L.
    J Invasive Cardiol; 2013 Mar 17; 25(3):114-7. PubMed ID: 23468438
    [Abstract] [Full Text] [Related]

  • 39. Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation.
    Zhang Q, Zhang RY, Shen J, Zhang JS, Hu J, Yang ZK, Zhang X, Zheng AF, Shen WF.
    Chin Med J (Engl); 2008 Dec 05; 121(23):2379-83. PubMed ID: 19102952
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 69.